DE69620027D1 - Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs - Google Patents

Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs

Info

Publication number
DE69620027D1
DE69620027D1 DE69620027T DE69620027T DE69620027D1 DE 69620027 D1 DE69620027 D1 DE 69620027D1 DE 69620027 T DE69620027 T DE 69620027T DE 69620027 T DE69620027 T DE 69620027T DE 69620027 D1 DE69620027 D1 DE 69620027D1
Authority
DE
Germany
Prior art keywords
eliprodil
retina
tension
treatment
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620027T
Other languages
English (en)
Other versions
DE69620027T2 (de
Inventor
A Kapin
Desantis, Jr
Bernard Scatton
Salomon Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of DE69620027D1 publication Critical patent/DE69620027D1/de
Application granted granted Critical
Publication of DE69620027T2 publication Critical patent/DE69620027T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69620027T 1996-01-02 1996-12-17 Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs Expired - Fee Related DE69620027T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58200396A 1996-01-02 1996-01-02
PCT/EP1996/005671 WO1997024123A1 (en) 1996-01-02 1996-12-17 Use of polyamine site antagonist for the manufacture of a medicament for the treatment of ischemic disorders of the eye

Publications (2)

Publication Number Publication Date
DE69620027D1 true DE69620027D1 (de) 2002-04-25
DE69620027T2 DE69620027T2 (de) 2002-09-05

Family

ID=24327451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620027T Expired - Fee Related DE69620027T2 (de) 1996-01-02 1996-12-17 Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs

Country Status (12)

Country Link
US (1) US6020352A (de)
EP (1) EP0871446B1 (de)
JP (1) JP2000507205A (de)
AT (1) ATE214605T1 (de)
AU (1) AU716670B2 (de)
CA (1) CA2241913A1 (de)
DE (1) DE69620027T2 (de)
DK (1) DK0871446T3 (de)
ES (1) ES2171233T3 (de)
HK (1) HK1016068A1 (de)
PT (1) PT871446E (de)
WO (1) WO1997024123A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620350D0 (en) 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
KR20020002356A (ko) * 1998-10-27 2002-01-09 제임스 에이. 아노 외부 망막 손상의 치료
US20030212107A1 (en) * 2001-05-10 2003-11-13 Kapin Michael A. R-reliprodil for treating glaucoma
CA2556589A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
GB2432526A (en) * 2005-11-24 2007-05-30 Arakis Ltd Use of ifenprodil for the treatment of ophthalmic diseases
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment

Also Published As

Publication number Publication date
AU716670B2 (en) 2000-03-02
DK0871446T3 (da) 2002-04-15
EP0871446B1 (de) 2002-03-20
ES2171233T3 (es) 2002-09-01
ATE214605T1 (de) 2002-04-15
EP0871446A1 (de) 1998-10-21
PT871446E (pt) 2002-08-30
WO1997024123A1 (en) 1997-07-10
HK1016068A1 (en) 1999-10-29
US6020352A (en) 2000-02-01
AU1373997A (en) 1997-07-28
JP2000507205A (ja) 2000-06-13
DE69620027T2 (de) 2002-09-05
CA2241913A1 (en) 1997-07-10

Similar Documents

Publication Publication Date Title
FI961809A (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69521620T2 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
NO20030724D0 (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69620027T2 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
DK217588A (da) 17beta-(cyclopropylamino)-androst-5-en-3beta-olderivater, deres fremstilling og anvendelse som laegemidler
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE59209728D1 (de) VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE69525631D1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69701258T2 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems
ATE230608T1 (de) Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit
ATE192336T1 (de) Verwendung von bifemelan zur herstellung eines arzneimittels zur behandlung der hyperkinesie
DE69919995D1 (de) Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis
ATE300304T1 (de) Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8339 Ceased/non-payment of the annual fee